Lean body mass, muscle fibre size and muscle function in cancer patients during chemotherapy and 10 weeks exercise

Lønbro, Simon; Farup, Jean; Bentsen, Signe Elizabeth Hegnander; Voss, Thomas Schmidt; Rittig, Nikolaj; Wang, Jakob; Ørskov, Morten; Højris, Inger; Mikkelsen, Ulla Ramer

doi:10.17987/jcsm-cr.v2i1.26

Cited by 15 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 ) In weight loss programs for patients with blood cancer, it is important to set the exercise intensity as high as possible while still ensuring safety. Lønbro et al 10 ) reported that exercise therapy at a Borg Scale rating of 14–18 for patients with cancer (mainly breast cancer) undergoing chemotherapy resulted in no adverse events. A Borg scale rating of 10–13 has been used previously in patients undergoing HSCT.…”

Section: Discussionmentioning

confidence: 99%

Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study

Kasahara

Fujita

Jinbo³

et al. 2021

PRM

View full text Add to dashboard Cite

Background: A severely obese woman (39.8 kg/m 2 ) with relapsed acute myeloid leukemia was admitted to our hospital to undergo salvage chemotherapy followed by cord blood transplantation (CBT). Case: During the salvage chemotherapy period, a 70-day weight loss program addressing diet and exercise was administered. After the 70-day intervention, the patient’s body weight and body fat mass had decreased (8.6% and 15.0%, respectively) without any adverse events. The number of available cord blood units with total nucleated cells per body weight greater than 2 × 10 7 /kg was zero at admission and two after weight loss; therefore, CBT could be performed. Discussion: Considering this case, we suggest that a weight loss program combining exercise and nutrition therapy may help patients scheduled for hematopoietic stem cell transplantation by focusing on risk management.

show abstract

Section: Discussionmentioning

confidence: 99%

Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study

Kasahara

Fujita

Jinbo³

et al. 2021

PRM

View full text Add to dashboard Cite

show abstract

“…Muscle wasting has received increasing research efforts in recent years . Further research is warranted to investigate the role of decreased physical activity for the suppression of muscle anabolic signalling during the progression of cancer cachexia . Feeding can activate cachectic muscle mTOR and protein synthesis.…”

Section: Basic Sciencementioning

confidence: 99%

Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference

Ebner

Anker

Haehling

2020

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 12th Cachexia Conference held in Berlin, Germany, in December 2019. Herein, we summarize the biological and clinical significance of different strategies including antibodies that target Fn14, Spsb 1, SAA1 treatment, ZIP14, a MuRF1 inhibitor, and new diagnostic tools like T‐cell communication targets and cut‐offs for the detection of skeletal muscle wasting. Of particular interest were the transplantation of mesenchymal stromal cells and muscle stem cell communication. Importantly, one presentation discussed the effect of metal ion transporter ZIP14 loss that reduces cancer‐induced cachexia. The potential of anti‐ZIP14 antibodies and zinc chelation as anti‐cachexia therapy may require testing in patients with cancer cachexia. Large clinical studies were presented such as RePOWER (observational study of patients with primary mitochondrial myopathy), MMPOWER (treatment with elamipretide in patients with primary mitochondrial myopathy), and ACT‐ONE as well as new mouse models like the KPP mouse. Promising treatments include rapamycin analogue treatment, anamorelin, elanapril, glucocorticoids, SAA1, antibodies that target Fn14, and a MuRF1 inhibitor. Clinical studies investigated novel approaches, including the role of exercise. It remains a fact, however, that effective treatments for cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.

show abstract

“…24,25 Further research is warranted to investigate the role of decreased physical activity for the suppression of muscle anabolic signalling during the progression of cancer cachexia. 26 Feeding can activate cachectic muscle mTOR and protein synthesis. Stimulated contractions can attenuate muscle wasting and alter intramuscular cachectic signalling after the initiation of cachexia.…”

Section: Basic Sciencementioning

confidence: 99%

Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference

Ebner

Anker

Haehling

2019

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

This article highlights the updates from preclinical and clinical studies into the field of wasting disorders that were presented at the 11th Cachexia Conference held in Maastricht, the Netherlands, in December 2018. Herein, we summarize the biological and clinical significance of different markers and new diagnostic tools and cut‐offs for the detection of skeletal muscle wasting, including micro‐RNAs, siRNAs, epigenetic targets, the ubiquitin–proteasome system, mammalian target of rapamycin signalling, news in body composition analysis including the D3‐creatine dilution method, and electrocardiography that was modified to enable segmental impedance spectroscopy. Of particular interest were the beneficial effects of BIO101 on muscle cell differentiation, hypertrophy of myofibers associated with mammalian target of rapamycin pathways activation, and the effect of metal ion transporter ZIP14 loss that reduces cancer‐induced cachexia. The potential of anti‐ZIP14 antibodies and zinc chelation as anti‐cachexia therapy should be tested in patients with cancer cachexia. Big randomized studies were presented such as RePOWER (observational study of patients with primary mitochondrial myopathy), STRAMBO (influence of physical performance assessed as score and clinical testing), MMPOWER (treatment of elamipretide in subjects with primary mitochondrial myopathy), FORCE (examined differences in relative dose intensity and moderate and severe chemotherapy‐associated toxicities between a strength training intervention and a control group), and SPRINTT (effectiveness of exercise training in healthy aging). Effective treatments were urothelin A, rapamycin analogue treatment, epigenetic factor BRD 4 and epigenetic protein BET, and the gut pathobiont Klebsiella oxytoca . Clinical studies that investigated novel approaches, including urolithin A, the role of gut microbiota, metal ion transporter ZIP14, lysophosphatidylcholine and lysophosphatidylethanolamine, and BIO101, were described. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.

show abstract

Lean body mass, muscle fibre size and muscle function in cancer patients during chemotherapy and 10 weeks exercise

Cited by 15 publications

References 49 publications

Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study

Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study

Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference

Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference

Contact Info

Product

Resources

About